Lexeo Therapeutics (LXEO) Retained Earnings (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Retained Earnings of -$400.3 million for Q1 2026, down 741251.85% on a YoY basis from N/an in Q1 2025, and down 5.31% sequentially from -$380.1 million in Q4 2025.
Lexeo Therapeutics (LXEO) Retained Earnings (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Retained Earnings data on file, last reported at -$400.3 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 741251.85% year-over-year to -$400.3 million; the trailing twelve-month figure through Mar 2026 stood at -$400.3 million (down 741251.85% YoY), and the FY2025 full-year result was -$380.1 million, down 368962.14% from the prior year.
- Retained Earnings fell to -$400.3 million in Q1 2026, from -$380.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$13000.0 in Q2 2025 to a low of -$400.3 million in Q1 2026.
- A 5-year average of -$192.4 million and a median of -$203.3 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings surged 99.99% in 2025 and slumped 741251.85% in 2026, its largest moves.
- Tracing LXEO's Retained Earnings over 5 years: stood at -$115.4 million in 2022, then plunged by 57.51% to -$181.8 million in 2023, then surged by 99.94% to -$103000.0 in 2024, then slumped by 368962.14% to -$380.1 million in 2025, then fell by 5.31% to -$400.3 million in 2026.
- Business Quant data shows LXEO's Retained Earnings at -$400.3 million in Q1 2026, -$380.1 million in Q4 2025, and -$359.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Lexeo Therapeutics | 382.38 Mn | 382.38 Mn | - | -400.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400.33 Mn |
| Dec 31, 2025 | -380.13 Mn |
| Sep 30, 2025 | -359.20 Mn |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -54,000.00 |
| Dec 31, 2024 | -103,000.00 |
| Sep 30, 2024 | -254.20 Mn |
| Jun 30, 2024 | -224.76 Mn |
| Mar 31, 2024 | -224.80 Mn |
| Dec 31, 2023 | -181.84 Mn |
| Sep 30, 2023 | -167.65 Mn |
| Dec 31, 2022 | -115.45 Mn |